Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06311227 · ClinicalTrials.gov registry record · Phase 2

Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia

A Phase 2 study of Recurrent Hairy Cell Leukemia and Recurrent Hairy Cell Leukemia Variant, sponsored by National Cancer Institute (NCI).

Recruiting
Registry status
Phase 2
Development phase
20
Enrollment target
20
Study locations

NCT06311227 is a Phase 2 study of Recurrent Hairy Cell Leukemia and Recurrent Hairy Cell Leukemia Variant that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 20 participants, below the 79-participant average among 4 other Recurrent Hairy Cell Leukemia trials with a reported enrollment target (75% lower). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06311227, a Phase 2 study of Recurrent Hairy Cell Leukemia and Recurrent Hairy Cell Leukemia Variant, is actively recruiting participants, sponsored by National Cancer Institute (NCI).

RECRUITING
Registry status
Phase 2
Development phase
20 participants
Enrollment target
20
Study locations

Study Summary

This phase II trial tests how well venetoclax works in treating patients with hairy cell leukemia that has come back after a period of improvement (relapsed). Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival.

Conditions Studied

Recurrent Hairy Cell Leukemia Recurrent Hairy Cell Leukemia Variant

Interventions

  • PROCEDURE Biospecimen Collection
  • PROCEDURE Bone Marrow Aspiration
  • PROCEDURE Bone Marrow Biopsy
  • PROCEDURE Computed Tomography
  • PROCEDURE Lumbar Puncture

Study Locations (20)

Florida

  • UM Sylvester Comprehensive Cancer Center at Aventura - Aventura
  • UM Sylvester Comprehensive Cancer Center at Coral Gables - Coral Gables
  • UM Sylvester Comprehensive Cancer Center at Coral Springs - Coral Springs
  • UM Sylvester Comprehensive Cancer Center at Deerfield Beach - Deerfield Beach
  • UM Sylvester Comprehensive Cancer Center at Doral - Doral
  • UM Sylvester Comprehensive Cancer Center at Hollywood - Hollywood
  • University of Miami Miller School of Medicine-Sylvester Cancer Center - Miami
  • UM Sylvester Comprehensive Cancer Center at Kendall - Miami

Kansas

  • University of Kansas Cancer Center - Kansas City
  • University of Kansas Cancer Center-Overland Park - Overland Park
  • University of Kansas Hospital-Westwood Cancer Center - Westwood

Missouri

  • University of Kansas Cancer Center - Briarcliff - Kansas City
  • University of Kansas Cancer Center - North - Kansas City
  • University of Kansas Cancer Center - Lee's Summit - Lee's Summit

California

  • City of Hope Comprehensive Cancer Center - Duarte
  • City of Hope at Irvine Lennar - Irvine

Maryland

  • University of Maryland/Greenebaum Cancer Center - Baltimore
  • NCI - Center for Cancer Research - Bethesda

Ohio

  • University of Cincinnati Cancer Center-UC Medical Center - Cincinnati
  • Ohio State University Comprehensive Cancer Center - Columbus

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2024-12-16
Est. Completion 2027-05-20
Phase Phase 2

Sponsor

National Cancer Institute (NCI)

3,257 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06311227

The ClinicalTrials.gov registry entry for NCT06311227 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 79-participant average among 4 other Recurrent Hairy Cell Leukemia trials with a reported enrollment target (75% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Recurrent Hairy Cell Leukemia appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT06311227 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Florida, Kansas, Missouri.

Frequently Asked Questions

What is clinical trial NCT06311227 about?

NCT06311227 is a clinical study titled "Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia". This phase II trial tests how well venetoclax works in treating patients with hairy cell leukemia that has come back after a period of improvement (relapsed). Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2...

What is the current status of trial NCT06311227?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2024-12-16. Estimated completion is 2027-05-20.

What conditions does trial NCT06311227 study?

This clinical trial studies the following conditions: Recurrent Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia Variant.

What interventions are being tested in trial NCT06311227?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Bone Marrow Aspiration (PROCEDURE), Bone Marrow Biopsy (PROCEDURE), Computed Tomography (PROCEDURE), Lumbar Puncture (PROCEDURE).

Who is sponsoring clinical trial NCT06311227?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06311227 being conducted?

This trial has 20 study locations across California, Florida, Kansas, Maryland, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Recurrent Hairy Cell Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Recurrent Hairy Cell Leukemia

All registered trials for this condition

Recurrent Hairy Cell Leukemia Variant

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.